

# CITATION REPORT

List of articles citing

**Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab**

**DOI: 10.1002/hed.23961**

**Head and Neck, 2016, 38 Suppl 1, E165-71.**

**Source:** <https://exaly.com/paper-pdf/63405102/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. <i>Cancer</i> , <b>2016</b> , 122, 3472-3483	6.4	27
23	Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 758-766	4	7
22	The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 868-883	4	30
21	Patterns of Care for Elderly Patients With Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 767-774	4	20
20	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , <b>2017</b> , 123, 1345-1353	6.4	17
19	Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. <i>Oral Oncology</i> , <b>2018</b> , 79, 9-14	4.4	5
18	Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. <i>Head and Neck</i> , <b>2018</b> , 40, 2612-2620	4.2	1
17	Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. <i>Oral Oncology</i> , <b>2018</b> , 86, 132-140	4.4	15
16	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. <i>Cancer</i> , <b>2018</b> , 124, 4486-4494	6.4	14
15	Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age. <i>Oral Oncology</i> , <b>2018</b> , 84, 71-75	4.4	9
14	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. <i>Chemotherapy</i> , <b>2019</b> , 64, 48-56	3.2	3
13	Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2019</b> , 145, 1160-1167	3.9	6
12	Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 135, 39-46	7	3
11	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , <b>2019</b> , 41, 2410-2429	4.2	12
10	A descriptive epidemiological study on the treatment options for head and neck cancer: Transition before and after approval of cetuximab. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 330-336	2.6	1
9	Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. <i>International Journal of Clinical Oncology</i> , <b>2019</b> , 24, 468-475	4.2	9
8	Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 107-115	7.5	6

7	Prospect for application of mathematical models in combination cancer treatments. <i>Informatics in Medicine Unlocked</i> , <b>2021</b> , 23, 100534	5.3	3
6	nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. <i>Medical Oncology</i> , <b>2021</b> , 38, 35	3.7	1
5	Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. <i>Oncotarget</i> , <b>2017</b> , 8, 115513-115525	3.3	1
4	The Modern Concept of Using Radiation Therapy for Cancer of the Oral Cavity and the Oropharyngeal Area. <i>Medical Radiology and Radiation Safety</i> , <b>2020</b> , 65, 65-71	0.4	
3	Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.. <i>Head and Neck</i> , <b>2022</b> ,	4.2	0
2	Bioradiotherapy with Cetuximab May Reduce the Risk of Neck Node Relapse in Locoregionally Advanced Laryngeal Glottic Carcinoma: May HER1-Profile Be Useful in the Bioselection of Patients?. <b>2022</b> , 12, 1489		0
1	Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin. <b>2023</b> , 24, 147-161		0